Melanoma vaccines: possible progress after years of frustration?
Schmidt
Charlie
C
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD / Q000187:drug effects*; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines / Q000494:pharmacology* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D016219:Immunotherapy, Adoptive / Q000379:methods; D008113:Liver Neoplasms / Q000517:prevention & control / Q000821:virology; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control / Q000821:virology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000970:Antineoplastic Agents; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D019496:Cancer Vaccines